

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

EVERGREEN THERAGNOSTICS, INC.

Petitioner

— vs. —

ADVANCED ACCELERATOR APPLICATIONS SA

Patent Owner

CASE NO. PGR2021-00002

PETITION FOR
POST GRANT REVIEW OF U.S. PATENT NO. 10,596,278
(ALL CLAIMS)

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. GROUNDS FOR STANDING (37 C.F.R. § 42.204(a)).....	2
III. OVERVIEW OF THE TECHNOLOGY AND THE '278 PATENT	2
A. Background of the Technology	2
B. The '278 Patent	4
1. Summary of the Specification of the '278 Patent.....	4
2. Summary of the Claims of the '278 Patent.....	5
3. Summary of the Relevant Portions of the Prosecution History.....	5
IV. CLAIMS FOR WHICH PGR IS REQUESTED, PRECISE RELIEF REQUESTED, AND SPECIFIC STATUTORY GROUNDS ON WHICH THE CHALLENGE IS BASED (37 C.F.R. § 42.22(a) AND 37 C.F.R. § 42.204(b))	8
A. Prior Art Patents and Printed Publications Relied Upon	8
B. Level of Ordinary Skill in the Art	13
C. Claim Construction	13
D. Overview of the Prior Art.....	14
1. Maus (Ex. 1009).....	14
2. Kwekkeboom (Ex. 1010).....	17
3. Prior art disclosing routine use of an acetic acid/sodium acetate buffer to maintain pH during complexation	17
4. The '536 Patent (Ex. 1013).....	19
5. de Blois (Ex. 1017)	19

6.	SEC Statement (Ex. 1018)	20
7.	Luna-Gutierrez (Ex. 1025).....	21
8.	Scott (Ex. 1015)	21
E.	Challenge 1: Independent Claim 1 and Dependent Claims 8-17 and 19 Are Anticipated by Maus (Ex. 1009)	22
1.	Independent Claim 1	22
2.	Dependent Claims 8-17 and 19.....	26
F.	Challenge 2: Independent Claim 1 and Dependent Claims 8-17 and 19 Would Have Been Obvious Over Maus (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010)	29
1.	Independent Claim 1	29
2.	Dependent Claims 8-17 and 19.....	32
G.	Challenge 3: Dependent Claims 2-4 Would Have Been Obvious Over Maus (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010) Further in View of the Knowledge of a POSA that Ascorbic Acid and Sodium Ascorbate Are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015)	34
1.	Claim 2	34
2.	Claim 3	36
3.	Claim 4.....	36
H.	Challenge 4: Dependent Claim 15 Would Have Been Obvious Over Maus (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010) Further in View of de Blois (Ex. 1017) and SEC Statement (Ex. 1018).....	37
I.	Challenge 5: Dependent Claim 18 Would Have Been Obvious Over Maus (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010) Further in View of the Knowledge of a POSA That the Volume of a Pharmaceutical Aqueous Solution Can Vary.....	39

J.	Challenge 6: Dependent Claims 5-7 Would Have Been Obvious Over Maus (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010), Further in View of De León-Rodríguez (Ex. 1014) and/or Banerjee (Ex. 1016).....	40
1.	Claim 5	41
2.	Claim 6	44
3.	Claim 7	45
K.	Challenge 7: Dependent Claims 5-7 Would Have Been Obvious Over Maus (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010), Further in View of the '536 Patent (Ex. 1013), Further in View of De León-Rodríguez (Ex. 1014) and/or Banerjee (Ex. 1016)	46
1.	Claim 5	46
2.	Claim 6	50
3.	Claim 7	51
L.	Challenge 8: Independent Claim 20 Would Have Been Obvious Over Maus (Ex. 1009) alone or in View of Kwekkeboom (Ex. 1010) Further in View of Knowledge that Ascorbic Acid and Sodium Ascorbate Are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015) Further in View of De León-Rodríguez (Ex. 1014) and/or Banerjee (Ex. 1016)	52
1.	A pharmaceutical aqueous solution	53
2.	comprising: (a) a complex formed by (ai) the radionuclide ¹⁷⁷ Lu (Lutetium-177) in a concentration that it provides a volumetric radioactivity of from 250 to 500 MBq/mL, and (aii) DOTA-TATE or DOTA-TOC	53
3.	(b) the stabilizers against radiolytic degradation comprising (bi) gentisic acid in a concentration of from 0.5 to 1 mg/mL and (bii) ascorbic acid in a concentration of from 2.0 to 5.0 mg/mL.....	53

4. (c) diethylenetriaminepentaacetic acid (DTPA) or a salt thereof in a concentration of from 0.01 to 0.10 mg/mL54
 5. (d) an acetate buffer composed of: (di) acetic acid in a concentration of from 0.3 to 0.7 mg/mL; and (dii) sodium acetate in a concentration from 0.4 to 0.9 mg/mL54
 6. wherein the pharmaceutical aqueous solution has less than 1% ethanol.....55
 7. the radiochemical purity (determined by HPLC) of the solution is maintained at $\geq 95\%$ for at least 72 h when stored at 25° C.....55
- M. Challenge 9: Independent Claim 20 Would Have Been Obvious Over Maus (Ex. 1009) Alone or in View of Kwekkeboom (Ex. 1010) Further in View of the '536 Patent (Ex. 1013) Further in View of the Knowledge of a POSA that Ascorbic Acid and Sodium Ascorbate Are Interchangeable as Radiolytic Stabilizers as Evidenced by Scott (Ex. 1015) Further in View of De León-Rodríguez (Ex. 1014) and/or Banerjee (Ex. 1016)56
1. A pharmaceutical aqueous solution57
 2. comprising: (a) a complex formed by (ai) the radionuclide ¹⁷⁷Lu (Lutetium-177) in a concentration that it provides a volumetric radioactivity of from 250 to 500 MBq/mL, and (aii) DOTA-TATE or DOTA-TOC57
 3. (b) the stabilizers against radiolytic degradation comprising (bi) gentisic acid in a concentration of from 0.5 to 1 mg/mL and (bii) ascorbic acid in a concentration of from 2.0 to 5.0 mg/mL.....57
 4. (c) diethylenetriaminepentaacetic acid (DTPA) or a salt thereof in a concentration of from 0.01 to 0.10 mg/mL58
 5. (d) an acetate buffer composed of: (di) acetic acid in a concentration of from 0.3 to 0.7 mg/mL; and (dii) sodium acetate in a concentration from 0.4 to 0.9 mg/mL58

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.